Lilly’s weight-loss drug reduces sleep apnea severity in late-stage trials
Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped reduce episodes of irregular breathing associated with a common sleep-related disorder in two late-stage trials, paving the way for expanding use of the drug.